Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Fungal Infection Reports
Published in: Current Fungal Infection Reports 4/2018

01-12-2018 | Current Management of Fungal Infections (J Maertens, Section Editor)

Cryptococcosis in Patients with Hematologic Diseases

Authors: Mariana Guarana, Jose Ernesto Vidal, Marcio Nucci

Published in: Current Fungal Infection Reports | Issue 4/2018

Login to get access

Abstract

Purpose of Review

In this paper, we reviewed the epidemiology, diagnosis, and treatment of cryptococcosis in patients with hematologic malignancies. We reviewed all case series of cryptococcosis in different hematologic conditions, and looked at epidemiologic trends considering the new antineoplastic drugs introduced in the treatment of hematologic malignancies.

Recent Findings

Case series of cryptococcosis in patients with hematologic malignancies are scarce. We identified an increase in the proportion of cases of cryptococcosis occurring in patients with hematologic malignancies, and many case reports of cryptococcosis in patients receiving ibrutinib, a Bruton kinase inhibitor used in the treatment of chronic lymphoproliferative diseases.

Summary

Cryptococcosis is uncommon in patients with hematologic malignancies, but its occurrence may be associated with poor outcome. Hematologists should be aware of this complication if patients develop neurologic symptoms or present with pulmonary infiltrates that do not improve with antibiotics.
Literature
1.
•• Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin N Am. 2016;30(1):179–206 Comprehensive review paper on cryptococcosis. CrossRef
2.
•• Elsegeiny W, Marr KA, Williamson PR. Immunology of cryptococcal infections: developing a rational approach to patient therapy. Front Immunol. 2018;9:651 This study reviews the interactions between host defenses and Cryptococcus and the patterns of clinical presentation and evolution based on these interactions. CrossRef
3.
Torrey FA. Cutaneous torulosis in a patient with Hodgkin’s disease. Arch Dermatol Syphilol. 1947;55(5):738.
4.
Gendel BR, Ende M, Norman SL. Cryptococcosis; a review with special reference to apparent association with Hodgkin’s disease. Am J Med. 1950;9(3):343–55.CrossRef
5.
Rodger RC, Terry LL, Binford CH. Histoplasmosis, cryptococcosis and tuberculosis complicating Hodgkin’s disease; report of a case. Am J Clin Pathol. 1951;21(2):153–7.CrossRef
6.
Zelman S, O'Neil RH, Plaut A. Disseminated visceral torulosis without nervous system involvement with clinical appearance of granulocytic leukemia. Am J Med. 1951;11(5):658–64.CrossRef
7.
8.
Symmers WS. Torulosis; a case mimicking Hodgkin's disease and rodent ulcer and a presumed case of pulmonary torulosis with acute dissemination. Lancet. 1953;265(6795):1068–74.CrossRef
9.
Levene M, Michaels L. Acute disseminated torulosis associated with Hodgkin’s disease. J Clin Pathol. 1955;8(3):201–6.CrossRef
10.
Misch KA. Torulosis associated with Hodgkin’s disease. J Clin Pathol. 1955;8(3):207–10.CrossRef
11.
Goodman HL. Cryptococcosis associated with Hodgkin’s disease. N Y State J Med. 1956;56(9):1493–7.PubMed
12.
Burrows B, Barclay WR. Combined cryptococcal and tuberculous meningitis complicating reticulum cell sarcoma. Am Rev Tuberc. 1958;78(5):760–8.PubMed
13.
Gowing NF. Observations on a case of torulosis associated with Hodgkin’s disease. Proc R Soc Med. 1958;51(7):494–6.PubMedPubMedCentral
14.
Gruhn JG, Sanson J. Mycotic infections in leukemic patients at autopsy. Cancer. 1963;16:61–73.CrossRef
15.
Bodey GP. Fungal infections complicating acute leukemia. J Chronic Dis. 1966;19(6):667–87.CrossRef
16.
Casazza AR, Duvall CP, Carbone PP. Infection in lymphoma. Histology, treatment, and duration in relation to incidence and survival. JAMA. 1966;197(9):710–6.CrossRef
17.
Kaplan MH, Rosen PP, Armstrong D. Cryptococcosis in a cancer hospital: clinical and pathological correlates in forty-six patients. Cancer. 1977;39(5):2265–74.CrossRef
18.
Kontoyiannis DP, Peitsch WK, Reddy BT, Whimbey EE, Han XY, Bodey GP, et al. Cryptococcosis in patients with cancer. Clin Infect Dis. 2001;32(11):E145–50.CrossRef
19.
Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001;33(5):690–9.CrossRef
20.
Pagano L, Fianchi L, Caramatti C, D'Antonio D, Melillo L, Caira M, et al. Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection. Haematologica. 2004;89(7):852–6.PubMed
21.
Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068–75.PubMed
22.
Schmalzle SA, Buchwald UK, Gilliam BL, Riedel DJ. Cryptococcus neoformans infection in malignancy. Mycoses. 2016;59(9):542–52.CrossRef
23.
• Wang RY, Chen YQ, Wu JQ, et al. Cryptococcosis in patients with hematological diseases: a 14-year retrospective clinical analysis in a Chinese tertiary hospital. BMC Infect Dis. 2017;17(1):463 This is a case series of 33 patients with hematologic diseases who developed cryptococcosis. The authors provide a comparison between patients with neoplastic and non-neoplastic hematologic diseases. CrossRef
24.
• Cogliati M, Prigitano A, Esposto MC, et al. Epidemiological trends of cryptococcosis in Italy: molecular typing and susceptibility pattern of Cryptococcus neoformans isolates collected during a 20-year period. Med Mycol 2018. The authors describe epidemiologic trends of cryptococcosis in Italy, and show that the proprotion of patients with hematologic diseases has increased over time.
25.
Benetatos L, Hatzimichael E, Vassou A, Bourantas KL. Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient. Leuk Res. 2007;31(1):119–20.CrossRef
26.
Chim CS, Liang R, Wong SS, Yuen KY. Cryptococcal infection associated with fludarabine therapy. Am J Med. 2000;108(6):523–4.CrossRef
27.
Costa P, Luzzati R, Nicolato A, Perboni G, Scalzini A, Lazzarini L, et al. Cryptococcal meningitis and intracranial tuberculoma in a patient with Waldenstrom’s macroglobulinemia treated with fludarabine. Leuk Lymphoma. 1998;28(5–6):617–20.CrossRef
28.
Leenders A, Sonneveld P, de MS. Cryptococcal meningitis following fludarabine treatment for chronic lymphocytic leukemia. Eur J Clin Microbiol Infect Dis. 1995;14(9):826–8.CrossRef
29.
Marchand T, Revest M, Tattevin P, Chevrier S, Poullot E, Lamy T, et al. Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(3):643–5.CrossRef
30.
Audeh YM, Gruszecki AC, Cherrington A, Reddy VV. Hairy cell leukemia with concurrent cryptococcus infection. Am J Hematol. 2003;72(3):223–4.CrossRef
31.
Dincol G, Kahraman R. Cryptococcus neoformans meningitis in a patient with hairy cell leukemia. Am J Hematol. 2006;81(5):387.CrossRef
32.
Ikpeazu EV, Kaplon MK. Cryptococcal meningitis occurring at 19 months after cladribine therapy for hairy cell leukemia. Eur J Haematol. 1998;61(4):286–7.CrossRef
33.
Cruz D, Costa P, Sagues M. Meningeal cryptococcosis in a patient with angioimmunoblastic lymphoma treated with alemtuzumab. Med Clin (Barc ). 2018.
34.
Henn A, Mellon G, Benoit H, et al. Disseminated cryptococcosis, invasive aspergillosis, and mucormycosis in a patient treated with alemtuzumab for chronic lymphocytic leukaemia. Scand J Infect Dis. 2014;46(3):231–4.CrossRef
35.
Hotz C, Ingen-Housz-Oro S, Tran Van NJ, et al. Pulmonary cryptococcoma in a patient with Sezary syndrome treated with alemtuzumab. Eur J Dermatol 2011; 21(6):1018–1020.
36.
Bassetti M, Repetto E, Mikulska M, Miglino M, Clavio M, Gobbi M, et al. Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature. J Chemother. 2009;21(2):211–4.CrossRef
37.
Liu J, Mouhayar E, Tarrand JJ, Kontoyiannis DP. Fulminant Cryptococcus neoformans infection with fatal pericardial tamponade in a patient with chronic myelomonocytic leukaemia who was treated with ruxolitinib: case report and review of fungal pericarditis. Mycoses. 2018;61(4):245–55.CrossRef
38.
Hirano A, Yamasaki M, Saito N, Iwato K, Daido W, Funaishi K, et al. Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis. Respir Med Case Rep. 2017;22:87–90.PubMedPubMedCentral
39.
Chen CC, Chen YY, Huang CE. Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib. Ann Hematol. 2016;95(2):361–2.CrossRef
40.
Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest. 2013;143(5):1478–9.CrossRef
41.
Stankowicz M, Banaszynski M, Crawford R. Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia. J Oncol Pharm Pract 2018;1078155217752078, 107815521775207.
42.
Baron M, Zini JM, Challan BT, et al. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis. Leuk Lymphoma. 2017;58(12):2981–2.CrossRef
43.
Okamoto K, Proia LA, Demarais PL. Disseminated Cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib. Case Rep Infect Dis. 2016;2016:4642831.PubMedPubMedCentral
44.
Sudhakaran S, Bashoura L, Stewart J, Balachandran DD, Faiz SA. Pulmonary Cryptococcus presenting as a solitary pulmonary nodule. Am J Respir Crit Care Med. 2017;196(9):1217–8.CrossRef
45.
Messina JA, Maziarz EK, Spec A, Kontoyiannis DP, Perfect JR. Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib. Open Forum Infect Dis. 2017, 4(1):ofw261.
46.
Swan CD, Gottlieb T. Cryptococcus neoformans empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature. BMJ Case Rep. 2018;2018.
47.
Sun K, Kasparian S, Iyer S, Pingali SR. Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib. Ecancermedicalscience. 2018;12:836.PubMedPubMedCentral
48.
•• Varughese T, Taur Y, Cohen N, et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis. 2018;67(5):687–92 In this study, the authors characterize 43 patients who developed serious infections while on ibrutinib. Etiology and risk factors for infection are described. CrossRef
49.
•• Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955–9 The authors present the characteristics of 33 patients receivinb ibrutinib who developed invasive fungal disease. CrossRef
50.
Ajam T, Hyun G, Blue BJ, Rajeh N. Primary cutaneous cryptococcosis in a patient with chronic lymphocytic leukemia: a case report 3 ed 2016:1–3.
51.
Abid MB, Stromich J, Gundacker ND. Is ibrutinib associated with disseminated cryptococcosis with CNS involvement? Cancer Biol Ther. 2018:1–3.
52.
Parampalli YS, Stubig T, Cornez I, et al. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol. 2015;169(6):824–33.CrossRef
53.
Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122(23):3843–4.CrossRef
54.
Badar T, Burger JA, Wierda WG, O’Brien S. Ibrutinib: a paradigm shift in management of CLL. Expert Rev Hematol. 2014;7(6):705–17.CrossRef
55.
•• Rogers K. Ibrutinib and fungus: an invasive concern. Blood. 2018;131(17):1882–4 In this editorial, the author speculates on what mechanisms are involved in the possible increased risk of invasive fungal disease in patients receiving ibrutinib. CrossRef
56.
Pagano L, Caira M, Fianchi L. Pulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy. Ann Med. 2005;37(4):259–69.CrossRef
57.
Zinck SE, Leung AN, Frost M, Berry GJ, Muller NL. Pulmonary cryptococcosis: CT and pathologic findings. J Comput Assist Tomogr. 2002;26(3):330–4.CrossRef
58.
Yamada W, Yamada H, Murata K, Kosugi H, Asano Y, Mochizuki K, et al. Case of cryptococcal choroiditis in adult with T-cell leukemia/lymphoma. J Infect Chemother. 2018.
59.
De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–21.CrossRef
60.
Boulware DR, Rolfes MA, Rajasingham R, von Hohenberg M, Qin Z, Taseera K, et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis. 2014;20(1):45–53.CrossRef
61.
Sato Y, Osabe S, Kuno H, Kaji M, Oizumi K. Rapid diagnosis of cryptococcal meningitis by microscopic examination of centrifuged cerebrospinal fluid sediment. J Neurol Sci. 1999;164(1):72–5.CrossRef
62.
Antinori S. New insights into HIV/AIDS-associated cryptococcosis. ISRN AIDS 2013; 2013:471363, 1, 22.
63.
Arendrup MC, Bille J, Dannaoui E, Ruhnke M, Heussel CP, Kibbler C. ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. Bone Marrow Transplant. 2012;47(8):1030–45.CrossRef
64.
Makadzange AT, McHugh G. New approaches to the diagnosis and treatment of cryptococcal meningitis. Semin Neurol. 2014;34(1):47–60.CrossRef
65.
Tanner DC, Weinstein MP, Fedorciw B, Joho KL, Thorpe JJ, Reller L. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol. 1994;32(7):1680–4.PubMedPubMedCentral
66.
Jitmuang A, Panackal AA, Williamson PR, Bennett JE, Dekker JP, Zelazny AM. Performance of the cryptococcal antigen lateral flow assay in non-HIV-related cryptococcosis. J Clin Microbiol. 2016;54(2):460–3.CrossRef
67.
Vidal JE, Boulware DR. Lateral flow assay for cryptococcal antigen: an important advance to improve the continuum of HIV care and reduce cryptococcal meningitis-related mortality. Rev Inst Med Trop Sao Paulo. 2015;57(Suppl 19):38–45.CrossRef
68.
Jarvis JN, Harrison TS. Pulmonary cryptococcosis. Semin Respir Crit Care Med. 2008;29(2):141–50.CrossRef
69.
Baughman RP, Rhodes JC, Dohn MN, Henderson H, Frame PT. Detection of cryptococcal antigen in bronchoalveolar lavage fluid: a prospective study of diagnostic utility. Am Rev Respir Dis. 1992;145(5):1226–9.CrossRef
70.
Singh N, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis. 2008;46(2):e12–8.CrossRef
71.
Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2010;50(3):291–322.CrossRef
72.
Henao-Martinez AF, Chastain DB, Franco-Paredes C. Treatment of cryptococcosis in non-HIV immunocompromised patients. Curr Opin Infect Dis. 2018;31(4):278–85.PubMed
73.
Tenforde MW, Shapiro AE, Rouse B, et al. Treatment for HIV-associated cryptococcal meningitis. Cochrane Database Syst Rev. 2018;7:CD005647.PubMed
74.
Vidal JE, Penalva de Oliveira AC, Dauar RF, Boulware DR. Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America. Braz J Infect Dis. 2013;17(3):353–62.CrossRef
Metadata
Title
Cryptococcosis in Patients with Hematologic Diseases
Authors
Mariana Guarana
Jose Ernesto Vidal
Marcio Nucci
Publication date
01-12-2018
Publisher
Springer US
Published in
Current Fungal Infection Reports / Issue 4/2018
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-018-0332-y

Other articles of this Issue 4/2018

Current Fungal Infection Reports 4/2018 Go to the issue

Clinical Mycology Lab Issues (S Córdoba, Section Editor)

Zygomycete Fungi Infection in Colombia: Literature Review

Fungal Infections of Skin and Subcutaneous (A Bonifaz, Section Editor)

Association of Malassezia to Atopic Dermatitis

Current Management of Fungal Infections (J Maertens, Section Editor)

Patients with Primary Immunodeficiencies: How Are They at Risk for Fungal Disease?

Clinical Mycology Lab Issues (S Córdoba, Section Editor)

The Southern Endemic Zone of Paracoccidioidomycosis: Epidemiological Approach in Northeast Argentina

Current Management of Fungal Infections (J Maertens, Section Editor)

Diagnosing Invasive Mold Infections: What Is Next

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Pityriasis Versicolor: Treatment Update
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits